1Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya60286, Indonesia
10Departement of Public Health and Preventive Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia
11Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India
12Department of Microbiology and Immunology, Hirosaki UniversityGraduate School of Medicine, Aomori, Hirosaki, Japan
13Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Cipto Mangunkusumo National Central General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
14Department of Physiology and Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
15Department of Medicine, Gastroenterology and Hepatology Section, Baylor College of Medicine, Houston, TX, 77030, USA
16The Research Center for GLOBAL and LOCAL Infectious Disease (RCGLID), Oita University, Faculty of Medicine, Yufu, Japan
17Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia
2Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, 60132, Indonesia
3Departement of Internal Medicine, Faculty of Medicine, Universitas Muhammadiyah Surabaya, Surabaya, Indonesia
4Helicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia
5Department of Environmental Preventive Medicine, Faculty of Medicine, Oita University Faculty of Medicine, Yufu, Japan
6Department of Medical Biochemistry, Faculty of Medicine-Dr. Soetomo Teaching Hospital, University of Airlangga, Surabaya, Indonesia
7Department of Anatomic Pathology, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia
8Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
9Institute Tropical Disease, Universitas Airlangga, Surabaya, Indonesia
*Corresponding Author E-mail: muhammad-m@fk.unair.ac.id
Online published on 31 March, 2026.
Several biomarkers could identify colorectal cancer (CRC) including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and platelet to lymphocyte ratio (PLR). However, the advantages of this biomarkers for identifying late-stage CRC still not clearly described. We assessed the value of accuracy and the relationship of biomarkers with CRC. We collected secondary data from hospital medical records between 2018-2020. We analyzed 50 complete data of CEA, 25 of CA 19-9, and 202 of PLR. We found a significant correlation between CEA with M stage (p=0.002 AUC=0.667), CRC stages (p=0.021, AUC=0.665), and metastases organs (p=0.002 AUC=0.667). Positive significant correlation also between CA 19-9 with M stage (p=0.023 AUC=0.650), CRC stages (p=0.045 AUC=0.697), and metastases organ (p=0.023, AUC= 0.650). In addition, this study was reported significant correlation between PLR with metastases stage (p= 0.001, AUC=0.620), CRC stage (p=0.047, AUC=0.576) and metastases organ (p=0.003, AUC=0.604). CEA, CA 19-9, and PLR are not suitable for confirming the presence of CRC, particularly when determining its stage and metastasis. However, they can be valuable for identifying individuals who do not have CRC, allowing for the establishment of a negative classification. When trying to detect CRC cases, CEA and CA 19-9 can be used independently as markers, while PLR should be used in combination with another marker.
CEA, CA 19-9, PLR, Cancer, Colorectal
